🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

31 results for “experimental” Clear

  1. 36-71 months old children-experimental EV71 vaccine.

    Sinovac Research and Development Co.,

    Hand, Foot and Mouth Disease

    phase 3 mab completed

    1 trial

  2. DEXMEDETOMIDINE , 18F-DPA-714

    Pari Pharma GmbH

    Patients who survive a COVID ARDS in intensive care must be weaned off invasive mechanical ventilation as quickly as possible. 60% of these patients present with intensive care delirium, a serious event that causes excess mortality and potential acute and late complications, since 30% of patients who present with delirium develop cognitive sequelae. Severe neuroinflammation is considered to be one of the main pathophysiological mechanisms causing delirium during ventilatory weaning. In addition to its sedative properties, dexmedetomidine has neuroprotective effects. In certain experimental models, it reduces cerebral inflammation by acting directly on the microglial phenotype. The role of this chronic neuroinflammatory state on cognitive capacity and reserve is beginning to emerge in the literature, regardless of the initial stress (surgery, head injury or Alzheimer's-type dementia), and is therefore capable of influencing patients' quality of life. The assessment of this neuroinflammation using non-invasive tools would appear to be of prime importance in the management of post-COVID neuro injured patients, as well as the evaluation of potential neuroprotective agents such as dexmedetomidine.

    phase 3 small molecule active

    1 trial

  3. Experimental vaccine

    Sinovac Research and Development Co.,

    Poliomyelitis

    phase 3 mab completed

    1 trial

  4. Experimental: Tezepelumab

    AstraZeneca

    Asthma

    phase 3 mab completed

    1 trial

  5. Experimental: Venetoclax in combination with Decitabine (+-sorafenib)

    Kunming Hope of Health Hospital

    Elderly AML Patients

    phase 3 other active

    1 trial

  6. Three doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age

    Sinovac Research and Development Co.,

    Poliomyelitis

    phase 3 mab completed

    1 trial

  7. experimental anti-anxiety drug

    Jazz Pharmaceuticals Ireland Limited

    Anxiety Disorder

    phase 3 small molecule completed

    1 trial

  8. experimental vaccine

    Sinovac Research and Development Co.,

    Epidemic Meningitis

    phase 3 mab active

    4 trials

  9. Administration of experimental treatment association (sotorasib, panitumumab 5FU)

    NORTHWEST BIOTHERAPEUTICS INC

    Colorectal Carcinoma

    phase 2 small molecule active

    1 trial

  10. Experimental

    The First People's Hospital of Lianyungang

    Locally Advanced Rectal Cancer (LARC)

    phase 2 small molecule active

    1 trial

  11. Experimental 1 - DBS of bilateral NAc - 6 months of active stimulation -- > 6 months of sham stimulation

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine Use Disorder

    phase 2 other active

    1 trial

  12. Experimental: CHF6001 3200 μg

    Chiesi Farmaceutici S.p.A.

    Uncontrolled Asthma

    phase 2 small molecule terminated

    1 trial

  13. Experimental: tislelizumab+anlotinib

    The First People's Hospital of Lianyungang

    Thymic Carcinoma

    phase 2 small molecule active

    1 trial

  14. Low-dose experimental vaccine

    Sinovac Research and Development Co.,

    Herpes Zoster

    phase 2 mab active

    1 trial

  15. experimental group x-MAP

    The First People's Hospital of Lianyungang

    Metastatic Colorectal Cancer (mCRC)

    phase 2 other active

    1 trial

  16. experimental group: Bushen Culuan Decoction and Clomiphene Citrate Tablets placebo

    Universal Integrated

    Anovulatory Infertility

    phase 2 small molecule active

    1 trial

  17. nal-IRI /Experimental

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metastatic Gastric Adenocarcinoma

    phase 2 small molecule active

    1 trial

  18. A randomized, investigator masked pilot study to establish the experimental conditions and select the criteria to compare topical application of 2 methyl aminolevulinate creams: evaluation of protoporphyrin IX formation in the skin of healthy subjects.

    Substipharm

    None - Healthy subjects

    phase 1 other active

    1 trial

  19. An adaptive, randomized, double-blind, single-center, placebo-controlled first-in-human study evaluating safety, tolerability and exposure of single and multiple ascending doses of Lactobacillus expressing CXCL12 administered topically to experimentally induced skin wounds

    Lacuna Pharma Pty Ltd

    Wound healing

    phase 1 other active

    1 trial

  20. Experimental Vaccine 1

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19 Pneumonia

    phase 1 mab completed

    1 trial

  21. Study to evaluate the addition of an experimental drug, CC-90010, to the usual treatment of brain cancer after surgery

    Celgene Europe Limited

    Subjects with newly diagnosed WHO Grade IV glioblastoma (ndGBM) who have undergone complete or partial tumor resection

    phase 1 other active

    1 trial

  22. Experimental 23-valent PPV

    Sinovac Research and Development Co.,

    Pneumococcal Infections

    approved mab completed

    1 trial

  23. Experimental 23-valent Pneumococcal

    Sinovac Research and Development Co.,

    Pneumococcal Infections

    approved mab completed

    1 trial

  24. Experimental Group

    Sinovac Research and Development Co.,

    COVID-19

    approved mab completed

    4 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources